Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Pharma R&D Spinoffs Unlikely To Get 150 Percent Tax Exemptions (India)

This article was originally published in PharmAsia News

Executive Summary

India's finance ministry has indicated it is not likely to extend the tax exemptions for in-house research conducted by pharmaceutical companies operating in the country to stand-alone R&D firms. Companies such as Dr. Reddy's and Sun Pharma recently spun off their research arms into stand-alone companies expected to continue to receive the exemptions, which amount to deductions of up to 150 percent of research and development expenses. Ranbaxy and Nicholas Piramal also have announced plans to create separate companies for their R&D work. The finance ministry apparently is considering allegations of abuse of the exemptions and has been advised to drop them altogether. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel